A carregar...
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
(177)Lu-DOTA-HH1 ((177)Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of (177)Lu-HH1, (177)Lu-DOTA-rituximab ((177)Lu-rituximab) and non-specific (177)Lu-DOTA-IgG(1) ((177)Lu-Ig...
Na minha lista:
Publicado no: | PLoS One |
---|---|
Main Authors: | , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Public Library of Science
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4466226/ https://ncbi.nlm.nih.gov/pubmed/26066655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0128816 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|